ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 671

Validation of the Rexspa (Reductive X-Ray Score for Psoriatic Arthritis) in an Argentinean Cohort of Patients with Psoriatic Arthritis

Carolina Ayelen Isnardi1, Emilce E Schneeberger2, Fernando Dal Pra3, E. Scheines1,4, Andrea Lujan Coronel Ale5, Marina Natalia Fornaro6, Osvaldo Luis Cerda5 and Gustavo Citera5, 1Reumatology, Instituto de Rehabilitación Psicofísica, CABA, Argentina, 2Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 3Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 4Rheumatology, Hospital Manuel Rocca, Buenos Aires, Argentina, 5Rheumatology Section, Instituto de Rehabilitación Psicofísica, CABA, Argentina, 6Section of Rheumatology, Instituto de Rehabilitación Psicofísica, buenos aires, Argentina

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: psoriatic arthritis and radiography

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

There are many scores available to measure radiographic joint damage in patients with PsA, but most of them were developed for RA and then modified for PsA. These scores don´t evaluate juxtaarticular bone proliferation, which is included as an item in the CASPAR criteria. The aim of our study was to validate the Reductive X-Ray Score for Psoriatic Arthritis (ReXSPA) score in a cohort of patients with PsA.

Methods:

A cross-sectional study was carried out, patients ≥18 years old with PsA according to CASPAR criteria were included. Sociodemographic data, comorbidities, clinical characteristics, morning stiffness, pain and patient and physician global assessments (by NVS), joint count (66/68), dactylitis, enthesitis (MASES), cutaneous psoriasis (PASI), ESR and CRP were consigned. The self-questionnaires HAQ-A, BASDAI, BASFI, PsAQoL and DLQI were administered. The composite DAPSA and CPDAI indices were calculated and the presence of MDA was assessed. All patients underwent X-rays of the hands and feet in the anteroposterior view. Two blind readers for the clinical characteristics of the patients and previously trained, scored them by Sharp van der Heijde modified for PsA (PsA-SvdHm) and ReXSPA indexes (ICC>0.94). The ReXSPA score evaluates a total of 22 joints in hands and feet. It values joint narrowing and erosion according to PsA-SvdHm and proliferation by Ratingen score. Time to read and calculate both scores were measured. Statistical analysis: Student T and Chi2 test. Spearman correlation. Lineal regression analysis.

Results:

A total of 66 patients were included, half of them were female, median (m) age of 56 years (IQR 43-62.3) and m disease duration of 8 years (IQR 4-14.3). 132 X-Rays were scored according to PsA-SvdH [m 35 (IQR: 16.3-72.5)] and ReXSPA [m 22 (IQR: 7-46.3)]. Time to read them was significantly shorter with ReXSPA than PsA-SvdH (mean 5.8±2.1 vs 7.5±2.5 minutes, p<0.0001), as well as, time to calculate them (mean 26.5±14.7 vs 55.3±38.3 seconds, p<0.0001), respectively. The correlation between both indexes was excellent (Rho: 0.93). In the multivariate analysis, using both radiographic scores as dependent variable, the association with disease duration remained significantly associated with both of them, and in the case of ReXSPA also with age.

Conclusion:

The ReXSPA index has shown validity and a very good correlation with PsA-SvdH. It is quicker to read and calculate. Subsequent longitudinal evaluations will allow to demonstrate the validity of these findings and to determine if the evaluation of bone proliferation adds an additional advantage.


Disclosure: C. A. Isnardi, None; E. E. Schneeberger, None; F. Dal Pra, None; E. Scheines, None; A. L. Coronel Ale, None; M. N. Fornaro, None; O. L. Cerda, None; G. Citera, Novartis, Pfizer Inc, 2,AbbVie, Bristol-Myers Squibb, Eli Lilly, Genzyme, Novartis, Pfizer Inc, Roche, 5.

To cite this abstract in AMA style:

Isnardi CA, Schneeberger EE, Dal Pra F, Scheines E, Coronel Ale AL, Fornaro MN, Cerda OL, Citera G. Validation of the Rexspa (Reductive X-Ray Score for Psoriatic Arthritis) in an Argentinean Cohort of Patients with Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/validation-of-the-rexspa-reductive-x-ray-score-for-psoriatic-arthritis-in-an-argentinean-cohort-of-patients-with-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-the-rexspa-reductive-x-ray-score-for-psoriatic-arthritis-in-an-argentinean-cohort-of-patients-with-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology